Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer

Prostate

Volumn 67, Issue 9, 2007, Pages 933-942

  Noguchi, Masanori ^a,b   Yao, Akihisa ^a   Harada, Mamoru ^a   Nakashima, Osamu ^a   Komohara, Yoshihiro ^c   Yamada, Satoko ^a   Itoh, Kyogo ^a,b   Matsuoka, Kei ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Cancer vaccine; Immunotherapy; Prostate cancer; T cell

Indexed keywords

CD20 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HLA A24 ANTIGEN; IMMUNOGLOBULIN G; PEPTIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; BLOOD TOXICITY; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INJECTION SITE REACTION; INTERFERON PRODUCTION; LIVER TOXICITY; MALE; NEPHROTOXICITY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TISSUE MICROARRAY; VACCINATION;

AGED; ANTIGENS, CD45; CANCER VACCINES; HLA-A ANTIGENS; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; VACCINES, SUBUNIT;

EID: 34249692904     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20572     Document Type: Article

References (26)

1. Smart CR. The results of prostate cancer screening in the U.S. as reflected in the surveillance, epidemiology, and end results program. Cancer 1997;80:1835-1844.
2. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy: Patterns recurrence and cancer control. Urol Clin North Am 1997;24:395-406.
3. Stamey TA, Yemoto CM, McNeal JE, Sigal BM, Johnstone IM. Prostate cancer is highly predictable: A prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol 2000;163:1155-1160.
4. Monfette G, Dupont A, Labrie F. Temporary combination therapy with Flutamide and Tryptex as adjuvant to radical prostatectomy for the treatment of early stage prostate cancer. In: Labrie F, Lee F, Dupont A, editors. Early stage prostate cancer: Diagnosis and choice of therapy. Amsterdam: Elsevier Biomedical Division; 1989.
5. Macfarleane MT, Abi-Aad A, Stein A, Danella J, Belldegrun A, deKernion JB. Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer. J Urol 1993;150:132-134.
6. Oesterling JE, Andrews PE, Suman VJ, Zincke H, Myers RP. Preoperative androgen deprivation therapy: Artificial lowering of serum prostate specific antigen without downstaging the tumor. J Urol 1993;149:779-782.
7. Soloway MS, Sharifie R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) proatate cancer. J Urol 1995;154:424-428.
8. Klotz LH, Goldenberg SL, Jewett M, Barkin J, Chetner M, Fradet Y, Chin J, Laplants S. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post treatment PSA results-Canadian Urologic Oncology Group. Urology 1999;53:757-763.
9. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001;50:3-15.
10. Marchand M, van Baren N, Weynants P, Brichard V, Dreéno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vamwijck R, Liénard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jäger E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80:219-230.
11. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderich JR, Parkhust MA, Kawakami Y, Seipp CA, Einhorn JH, White DE. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-327.
12. Noguchi M, Kobayashi K, Suetugu N, Tomiyas K, Suekane S, Yamada A, Itoh K, Noda S. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 2003;57:80-92.
13. Noguchi M, Itoh K, Suekane S, Yao A, Suetsugu N, Katagiri K, Yamada A, Noda S. Phase I trial of patient-oriented vaccination in HLA-A2 positive patients with metastatic hormone refractory prostate cancer. Cancer Sci 2004;95:77-84.
14. Noguchi M, Itoh K, Suekane S, Morinaga A, Sukehiro A, Suetsugu N, Katagiri K, Yamada A, Noda S. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. Prostate 2004;60:32-45.
15. + HRPC patients. Prostate 2005;63:1-12.
16. + prostate cancer patients. Prostate 2003;57:152-159.
17. + prostate cancer patients. Cancer Sci 2003;94:622-627.
18. Mine T, Sato Y, Noguchi M, Sasatomi T, Gouhara R, Tsuda S, Tanaka S, Shomura H, Katagiri K, Rikimaru T, Shichijo S, Kamura T, Hashimoto T, Shirouzu K, Yamada A, Todo S, Itoh K, Yamana H. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing peptide-specific cellular responses. Clin Cancer Res 2004;10:929-937.
19. Noguchi M, Stamey TA, McNeal JE, Yemoto CEM. Assessment of morphometric measurements of prostate carcinoma volume. Cancer 2000;89:1056-1064.
20. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
21. Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Michael HJ. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 2002;53:109-117.
22. Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal A, Kenny GM, Troychak MJ, Salgaller ML, Boynton AL. Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 1999;39:54-59.
23. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18:3894-38903.
24. Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlovic S. Immunotherapy (APC8015, provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A phase 2 trial. Prostate 2004; 60:197-204.
25. Clement LT. Isoforms of the CD45 common leukocyte antigen family: Markers for human T-cell differentiation. J Clin Immunol 1992;12:1-10.
26. + T cells reactive to a class I tumor peptide. J Immunol 2004;172:2659-2667.